There are no known benefits for cyclooxygenase-2 selective inhibitors over nonspecific inhibitors relating to cardiac or renal function, and the known associations between NSAID use and renal failure [8] and heart failure [10,11] are likely to apply to cyclooxygenase-2 selective inhibitors. The gene discussed is PTGS2; the disease is heart failure.